IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
6
Bullish
2
Bearish
20
Neutral
6
Bullish
20
Bearish
14
Neutral
0
Bullish
18
Bearish
14
Neutral
0
Bullish
18
Bearish
14
Neutral
0
Bullish
18
Bearish
14
Neutral
0
Bullish
18
Investor Presentation
Q4 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q4 FY25
Venmax Drugs & Pharmaceuticals Ltd (VENMAX) is currently trading at 14.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Venmax Drugs & Pharmaceuticals Limited is a small-cap Indian pharmaceutical company engaged in pharmaceutical products, drug intermediates, APIs, and operating a retail chain under the brand 'Ananya Pharma', with formulation support from Suzichem Labs and active R&D in oncology products to build a manufacturing-export capability. Fiscal 2026 revenue from operations surged to Rs. 802.49 lakh from Rs. 80.73 lakh a year ago, a near tenfold increase driven primarily by trading/stock-in-trade activity and rapid scale-up of operations, while the company posted a modest standalone profit of Rs. 24.82 lakh and basic EPS of Rs. 0.21 for FY2026. The balance sheet expanded materially to Rs. 1,620.02 lakh at year-end, driven by a large increase in share application money and other current assets; management converted 6,344,000 warrants into equity, lifting reported share capital and providing significant financing for strategic initiatives and planned cGMP capex. Operating cash flow was highly negative at approximately Rs. (1,099.6) lakh for the year due to working capital build-up and large other financial assets, while financing activities supplied Rs. 973.73 lakh, highlighting near-term reliance on equity funding to support rapid operational expansion and planned investments. Strategic focus is on rolling out the 'Ananya Pharma' retail chain, scaling formulations via Suzichem Labs, and advancing oncology R&D and a proposed manufacturing unit with cGMP capability in Hyderabad, which collectively signal a deliberate transformation from trading/retail toward manufacturing and exports.
Over the past 52 weeks, Venmax Drugs & Pharmaceuticals Ltd has traded between a low of ₹12.51 and a high of ₹31.49. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 20.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Venmax Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 74.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 20.86 Cr, Venmax Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Venmax Drugs & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Venmax Drugs & Pharmaceuticals Ltd is 74.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Yes. Venmax Drugs said its equity shareholders approved the proposed Scheme of Amalgamation with Hatri Pharma Private Limited on October 24, 2026.
The NCLT-convened equity shareholders' meeting is scheduled for October 24, 2026, at 12:30 p.m. IST.
The equity shareholders meeting is scheduled for October 24, 2026, at 12:30 pm (IST).
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
24.35 | 23 Cr | 9.41 | 1.21 | 0.00 | 11.91 | 16.46 | 5.44 | ||
4.55 | 23 Cr | -1.38 | 0.46 | 0.00 | -26.30 | -22.21 | -24.96 | ||
0.18 | 22 Cr | -1.31 | 0.23 | 0.00 | -5.66 | -5.66 | -3.33 | ||
72.62 | 22 Cr | 29.74 | 1.82 | 0.00 | 6.05 | 9.36 | 5.46 | ||
14.40 | 21 Cr | 74.50 | 1.00 | 0.00 | 1.87 | 2.03 | 1.66 | ||
3.40 | 18 Cr | 456.75 | 2.41 | 0.00 | 0.56 | 0.30 | 0.37 | ||
10.25 | 18 Cr | 51.74 | 0.57 | 0.00 | 1.12 | 4.42 | 0.29 | ||
| Median: 7 Co. | — | 10.25 | 22 Cr | 29.74 | 1.00 | 0.00 | 1.12 | 2.03 | 0.37 |
Venmax Drugs & Pharmaceuticals Limited is a small-cap Indian pharmaceutical company engaged in pharmaceutical products, drug intermediates, APIs, and operating a retail chain under the brand 'Ananya Pharma', with formulation support from Suzichem Labs and active R&D in oncology products to build a manufacturing-export capability.
Fiscal 2026 revenue from operations surged to Rs. 802.49 lakh from Rs. 80.73 lakh a year ago, a near tenfold increase driven primarily by trading/stock-in-trade activity and rapid scale-up of operations, while the company posted a modest standalone profit of Rs. 24.82 lakh and basic EPS of Rs. 0.21 for FY2026.
The balance sheet expanded materially to Rs. 1,620.02 lakh at year-end, driven by a large increase in share application money and other current assets; management converted 6,344,000 warrants into equity, lifting reported share capital and providing significant financing for strategic initiatives and planned cGMP capex.
Operating cash flow was highly negative at approximately Rs. (1,099.6) lakh for the year due to working capital build-up and large other financial assets, while financing activities supplied Rs. 973.73 lakh, highlighting near-term reliance on equity funding to support rapid operational expansion and planned investments.
Strategic focus is on rolling out the 'Ananya Pharma' retail chain, scaling formulations via Suzichem Labs, and advancing oncology R&D and a proposed manufacturing unit with cGMP capability in Hyderabad, which collectively signal a deliberate transformation from trading/retail toward manufacturing and exports.
Pharmaceuticals & Biotechnology
Pharmaceuticals
21 Cr
Low Risk
74.5
39.5
23.4
1.0
31.49
12.51
Sales CAGR
Profit CAGR
ROE
ROCE
